Anti-Human VEGF (Bevacizumab)

Contact us
Leinco Technologies
Product Code: LEI-LT400
Product Group: Primary Antibodies
CodeSizePrice
LEI-LT400-CustomCustomEnquire
Quantity:
LEI-LT400-1.0mg1.0 mg£207.00
Quantity:
LEI-LT400-5.0mg5.0 mg£532.00
Quantity:
LEI-LT400-25mg25 mg£1,677.00
Quantity:
LEI-LT400-50mg50 mg£2,902.00
Quantity:
LEI-LT400-100mg100 mg£4,066.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Human
Antibody Isotype: Human IgG1κ
Antibody Clonality: Monoclonal
Antibody Clone: A4.6.1
Regulatory Status: RUO
Target Species: Human
Applications:
  • Blocking
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Flow Cytometry
  • Immunoprecipitation (IP)
  • Neutralisation
  • Western Blot (WB)
Shipping:
2 - 8°C Wet Ice
Storage:
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -80°C.?Avoid Repeated Freeze Thaw Cycles.

Further Information

Antigen Distribution:
VEGF is widely expressed in the thyroid, prostate, and various other tissues.
Concentration:
? 5.0 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
Recombinant human VEGF.
Long Description:
Bevacizumab is a monoclonal antibody that specifically recognizes vascular endothelial growth factor (VEGF). VEGF is a growth factor that participates in angiogenesis, vasculogenesis, and endothelial cell growth. It facilitates endothelial cell proliferation, cell migration, and the permeabilization of blood vessels. In addition, VEGF inhibits apoptosis. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the regression of tumor vascularization, normalization of remaining tumor vasculature, and inhibition of the formation of new tumor vasculature, thus inhibiting tumor growth.1 Anti-Human VEGF (Bevacizumab) utilizes the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research projects.
NCBI Gene:
7422
Purity:
?95% monomer by analytical SEC
Target:
VEGF

References

1. Pazdur, R. et al. (2018) Clin Cancer Res. 24(18):4365-70.